Financial Trends -- 5/10
Altria is a mature tobacco business in managed decline. Pricing power in cigarettes remains
strong but is increasingly strained by accelerating volume declines and Marlboro share erosion
(below 40% for the first time in Q4 2025). EPS growth is positive but decelerating at the exit
rate (+0.8% in Q4 2025). The smoke-free transition (on!, NJOY) is progressing slowly -- NJOY
effectively sidelined, on! growth stalled near-zero in H2 2025. The dividend is safe (77% payout)
but growing at a below-inflation pace. Overall: stable-but-shrinking cash flows with no
inflection point yet visible.
Weight: 25%
2025 Net Revenue
$23,279M
-3.1% YoY | 5th consecutive decline
2025 Adj Diluted EPS
$5.42
+5.9% YoY | Q4 exit rate only +0.8%
2025 EBITDA
$12,593M
+3.6% YoY | accelerating from +0.4%
Marlboro Retail Share
40.5%
-1.2pp YoY | dropped below 40% in Q4
Net Revenue Trajectory (Annual, USD M)
Revenue declining for 5 consecutive years, worsening to -3.1% in 2025.
Net revenue fell from $26.2B (2020) to $23.3B (2025) -- a steady erosion driven by cigarette
volume declines outrunning pricing. Smokeable revenue ex-excise declined -1.6% in 2025, while
oral tobacco (+1.2%) and e-vapor (-$13M) provided minimal offset. The pricing offset ratio
averaged ~0.72x in 2025, meaning volume declines are outrunning price increases. Consensus
expects continued contraction to ~$22.7B (2026E) and ~$22.2B (2027E).
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Revenue ($M) | $26,153M | $26,013M | $25,096M | $24,483M | $24,018M | $23,279M |
| YoY Growth | — | -0.5% | -3.5% | -2.4% | -1.9% | -3.1% |
| Smokeable Rev ex-Excise | $17,927M | $18,112M | $18,187M | $17,887M | $17,735M | $17,443M |
| Smokeable YoY | — | 1.0% | 0.4% | -1.6% | -0.8% | -1.6% |
| Oral Tobacco Rev ex-Excise | $2,403M | $2,476M | $2,461M | $2,555M | $2,671M | $2,704M |
| Oral Tobacco YoY | — | 3.0% | -0.6% | 3.8% | 4.5% | 1.2% |
2026E ~$22.7B, 2027E ~$22.2B consensus. E-vapor segment contributed -$13M in 2025 (NJOY sidelined). Data sourced from Daloopa.
Consolidated EBITDA (Annual, USD M)
EBITDA accelerating: +3.6% in 2025 after near-flat +0.4% in 2024.
Consolidated EBITDA of $12.6B remains enormous for a company with $23.3B revenue, reflecting
pricing power and cost discipline. The 2023 dip (-2.6%) was followed by a recovery to +3.6%
in 2025. Oral tobacco adjusted OCI margin is stable at 67.9%. Management guides mid-single-digit
EPS CAGR through 2028, implying EBITDA should grow at a similar pace aided by duty drawback
benefits ($300M-$375M CapEx in 2026, payback under 1 year).
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| EBITDA ($M) | $11,324M | $12,124M | $12,433M | $12,109M | $12,157M | $12,593M |
| YoY Growth | — | 7.1% | 2.5% | -2.6% | 0.4% | 3.6% |
| Oral Tob OCI Margin | 71.7% | 68.5% | 66.3% | 67.4% | 67.8% | 67.9% |
Oral Tob Adj OCI margin shown for reference. 2026E ~$12.8B, 2027E ~$13.1B consensus. Data sourced from Daloopa.
Adjusted Diluted EPS Trajectory
EPS growth positive but exit rate is weak -- Q4 2025 only +0.8% YoY.
Full-year 2025 EPS of $5.42 (+5.9%) was above 2024 (+3.4%), aided by share buybacks, MSA legal
fund expiration, and pricing. However, growth accelerated through mid-2025 (Q2: +9.9%) then
decelerated sharply to +0.8% in Q4 as tailwinds lapped. 2026 guidance of $5.56-$5.72 (+2.5% to
+5.5%) is below historical range and back-end loaded (duty drawback weighted to H2).
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Adj Diluted EPS | $4.4 | $4.6 | $4.8 | $5.0 | $5.1 | $5.4 |
| YoY Growth | — | 5.7% | 5.0% | 2.3% | 3.4% | 5.9% |
| Diluted Shares (M) | 1,859 | 1,845 | 1,804 | 1,777 | 1,718 | 1,683 |
2026E: $5.56-$5.72 (guided). 2027E ~$5.90 consensus. Mid-single-digit CAGR target through 2028. Data sourced from Daloopa.
Cigarette Volume Decline (Annual, Bn Sticks)
Cigarette volumes declined 39% from 101.4B (2020) to 61.8B (2025).
Volume decline has been running at -9% to -11% annually since 2022, far exceeding the industry
rate by 1.5-2.0pp. Management attributes the underperformance to Marlboro premium positioning
and Basic cannibalization math. The industry decline showed signs of moderation in Q4 2025
(-6.5% vs -8% FY) as illicit e-vapor enforcement begins to bite. Management revised the
cross-category impact estimate DOWN to 2-3% (from 3-4%), suggesting some stabilization.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cig Shipments (Bn) | 101.4 | 93.8 | 84.7 | 76.3 | 68.6 | 61.8 |
| MO YoY Decline | — | -7.5% | -9.7% | -9.9% | -10.1% | -9.9% |
| MO Adj Decline (inv-adj) | -2.0% | -6.0% | -9.5% | -10.0% | -11.0% | -9.5% |
| Industry Adj Decline | — | -5.5% | -8.0% | -8.0% | -9.0% | -8.0% |
| MO Underperf vs Industry (pp) | — | -0.5% | -1.5% | -2.0% | -2.0% | -1.5% |
Adj decline = inventory-adjusted. MO underperforming industry by 1.5-2.0pp consistently. Data sourced from Daloopa.
Pricing vs Volume -- Smokeable Segment (Quarterly, $M)
Pricing offset ratio averaged ~0.72x in 2025 -- volume declines outrunning price.
Pricing realization decelerated from $517-$524M/quarter in late 2024 to $353-$359M/quarter in
late 2025, a concerning trend. In H2 2024 the offset ratio briefly hit ~0.95x but reverted in
2025 as volume declines remained elevated and pricing growth moderated. Net smokeable revenue
impact was negative every quarter, meaning the top line is structurally shrinking.
| Quarter | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pricing ($M) | +$472M | +$488M | +$420M | +$287M | +$403M | +$524M | +$517M | +$524M | +$491M | +$477M | +$359M | +$353M |
| Vol Drag ($M) | -654M | -542M | -725M | -473M | -589M | -846M | -556M | -537M | -775M | -639M | -530M | -482M |
| Net Impact ($M) | -182M | -54M | -305M | -186M | -186M | -322M | -39M | -13M | -284M | -162M | -171M | -129M |
Pricing offset ratio = Pricing / abs(Vol Drag). Ratio below 1.0x means volume losses exceed pricing gains. Data sourced from Daloopa.
Marlboro Retail Share Erosion (Quarterly)
Marlboro dropped below 40% share for the first time in Q4 2025.
Share erosion has accelerated from -0.1pp (Q2 2024) to -1.5pp (Q4 2025). Drivers include
discount segment growth from consumer income pressure, illicit e-vapor cross-category impact,
and strategic deployment of Basic in ~30,000 stores. Management maintains Marlboro retains
59.4% share of the premium segment (FY2025), but total category share erosion is accelerating
and the breach of 40% is a symbolically important milestone.
| Quarter | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marlboro Share (%) | 42.0% | 42.1% | 42.3% | 42.2% | 42.0% | 42.0% | 41.7% | 41.3% | 41.0% | 41.0% | 40.4% | 39.8% |
| YoY Change (pp) | — | — | — | — | 0.0% | -0.1% | -0.6% | -0.9% | -1.0% | -1.0% | -1.3% | -1.5% |
Retail share of total cigarette category. Premium segment share was 59.4% in FY2025. Data sourced from Daloopa.
on! Nicotine Pouch Volume (Quarterly, M Cans)
on! growth has decelerated dramatically from ~40%+ YoY in 2024 to near-zero in H2 2025.
Annual on! volumes of 177.8M cans (+10.9% YoY) mask the sharp deceleration: Q3 and Q4 2025
each grew only +0.7% YoY. Competitive intensity increased significantly (ZYN promotions,
synthetic nicotine entrants) -- competitor pricing down 12% YoY while on! pricing up 3%.
on! PLUS received FDA authorization (Dec 2025) and launched nationally in H1 2026, which
may re-accelerate growth. Helix (on!) was profitable for FY2025, ahead of original target.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| on! Shipments (M cans) | — | — | 82.5 | 114.3 | 160.3 | 177.8 |
| YoY Growth | — | — | — | 38.5% | 40.2% | 10.9% |
on! PLUS national launch planned H1 2026 (Mint, Wintergreen, Tobacco). Data sourced from Daloopa.
Dividend and Capital Return
60th consecutive dividend increase; 6.45% yield; 77% payout ratio.
Dividend per share of $4.16 in 2025 (+4.0% YoY) is well-covered by EPS of $5.42. Total dividends
paid grew from $6.6B (2022) to $7.0B (2025). Share buybacks totaled $3.4B in 2024 (73.5M shares,
largest in 20+ years, funded by ABI proceeds) and $1.0B in 2025. $1B remains under the $2B
authorization (expires end-2026). Shares declined from 1,859M (2020) to 1,674M (2025) -- an
aggregate 10% reduction. Buyback pace slowed significantly from 2024 elevated level.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Dividend/Share ($) | $3.4 | $3.5 | $3.8 | $3.8 | $4.0 | $4.2 |
| Div YoY Growth | — | 3.5% | 3.5% | 4.2% | 4.1% | 4.0% |
| Shares Outstanding (M) | 1,859 | 1,817 | 1,786 | 1,763 | 1,691 | 1,674 |
| Shares YoY | — | -2.3% | -1.7% | -1.3% | -4.1% | -1.0% |
2024 buyback of $3.4B (73.5M shares) was largest in 20+ years, funded by ABI proceeds. $1B remaining under $2B authorization. Data sourced from Daloopa.
Acceleration / Deceleration Analysis
| Signal | Detail | Direction |
|---|---|---|
| Revenue | -1.9% in 2024 to -3.1% in 2025; smokeable pricing offset weakening | Decelerating |
| Adj EPS | FY2025 +5.9% (better than 2024 +3.4%) but Q4 exit rate only +0.8% | Mixed |
| Cigarette Volumes | -11% in 2024 to -9.5% in 2025; industry improving -9% to -8% | Slight Improvement |
| on! Growth | +40% in 2024 to +11% in 2025 (and ~0% in H2); sharply decelerating | Sharply Decelerating |
| Marlboro Share | -0.4pp in 2024 to -1.2pp in 2025; dropped below 40% | Accelerating Decline |
| EBITDA | +0.4% in 2024 to +3.6% in 2025; accelerating | Accelerating |
| Dividend Growth | ~4% annually; stable; 60th consecutive increase | Stable |
| Share Reduction | -4.1% in 2024 (ABI proceeds) to -1.0% in 2025; pace slowed | Decelerating |
Score Derivation
| Factor | Assessment | Impact |
|---|---|---|
| Base Score | Stable, cash-generative business in structural decline with pricing power partially offsetting volume | 5.0 |
| EPS growth positive but decelerating at exit | Q4 2025 only +0.8% YoY; 2026 guide of +2.5-5.5% is below historical range | -0.5 |
| Marlboro share erosion accelerating | Below 40% for first time; -1.2pp in 2025 vs -0.4pp in 2024 | -0.5 |
| NJOY effectively sidelined | $2.2B+ in impairments; zero revenue contribution; no smoke-free inflection | -0.5 |
| on! growth stalled in H2 2025 | From ~40%+ YoY in 2024 to ~0% in H2 2025; competitive intensity risk | -0.5 |
| Strong dividend and capital return | 60 consecutive years of increases; 77% payout ratio; manageable debt (2x EBITDA) | +0.5 |
| EBITDA accelerating; duty drawback optionality | +3.6% in 2025 after +0.4%; KT&G duty drawback with sub-1-year payback | +0.5 |
| Pricing still robust | ~8-10% net realization in smokeable; partially offsetting volume | +0.5 |
| Industry volume moderation | Industry decline improving from -9% (2024) to -8% (2025); enforcement tailwind | +0.5 |
| Net Adjustment | -0.5 - 0.5 - 0.5 - 0.5 + 0.5 + 0.5 + 0.5 + 0.5 = 0.0 | 0.0 |
| Final Score | Base 5.0 plus 0.0 net adjustment | 5/10 |
Data sourced from Daloopa and MO earnings transcripts (Q3 2024 through Q4 2025). Calendar fiscal year.